Puma Biotechnology
PBYI
102 hedge funds and large institutions have $92.2M invested in Puma Biotechnology in 2021 Q4 according to their latest regulatory filings, with 20 funds opening new positions, 38 increasing their positions, 34 reducing their positions, and 33 closing their positions.
40% more call options, than puts
Call options by funds: $725K | Put options by funds: $519K
12% more repeat investments, than reductions
Existing positions increased: 38 | Existing positions reduced: 34
4.6% less ownership
Funds ownership: 78.88% → 74.27% (-4.6%)
11% less funds holding
Funds holding: 115 → 102 (-13)
39% less first-time investments, than exits
New positions opened: 20 | Existing positions closed: 33
59% less capital invested
Capital invested by funds: $226M → $92.2M (-$134M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
+$6.4M |
| 2 |
EP
Eversept Partners
New York
|
+$3.12M |
| 3 |
D.E. Shaw & Co
New York
|
+$2.98M |
| 4 |
Acadian Asset Management
Boston,
Massachusetts
|
+$1.94M |
| 5 |
Walleye Capital
New York
|
+$1.75M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FAM
Fred Alger Management
New York
|
-$17.3M |
| 2 |
PAI
Palo Alto Investors
Palo Alto,
California
|
-$9.77M |
| 3 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$9.11M |
| 4 |
ACM
AIGH Capital Management
Baltimore,
Maryland
|
-$6.06M |
| 5 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
-$5.97M |
PBYI Hedge Fund Activity: Q4 2021 in Review
102 of the 6,518 institutional investors tracked by Wall St. Rank reported a position in Puma Biotechnology (PBYI) for Q4 2021, worth a combined $92.2M — down 59% from $226M a quarter earlier.
Sellers outnumbered buyers: 33 funds closed out of PBYI and 20 opened new positions — a net loss of 13 holders — while 34 trimmed existing stakes and 38 added.
The largest buyer was Goldman Sachs, adding an estimated $6.4M. The largest seller was Fred Alger Management, exiting entirely with an estimated $17.3M sold.
- 102 institutional investors held Puma Biotechnology (PBYI) as of Q4 2021, down from 115 in Q3 2021.
- Funds reported $92.2M of Puma Biotechnology stock for Q4 2021, down 59% quarter-over-quarter.
- 20 funds opened new Puma Biotechnology positions in Q4 2021 and 33 closed out, a net change of -13 holders.
- The largest Puma Biotechnology buyer in Q4 2021 was Goldman Sachs, an estimated $6.4M added.
- The largest Puma Biotechnology seller in Q4 2021 was Fred Alger Management, an estimated $17.3M sold.
Based on aggregated 13F filings for Q4 2021.